Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $25.06 Consensus Target Price from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average recommendation of “Hold” by the twenty ratings firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $25.0588.

A number of equities research analysts have commented on the company. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, July 9th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a report on Wednesday, August 19th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Piper Sandler cut their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Finally, Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

Sarepta Therapeutics Stock Performance

SRPT opened at $20.86 on Monday. The company has a fifty day moving average price of $17.73 and a two-hundred day moving average price of $18.32. Sarepta Therapeutics has a 1-year low of $14.68 and a 1-year high of $25.32. The company has a market cap of $2.20 billion, a P/E ratio of -7.19, a price-to-earnings-growth ratio of 0.31 and a beta of 0.23. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to analysts’ expectations of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business’s revenue was down 34.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 EPS. Analysts predict that Sarepta Therapeutics will post 3.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC bought a new stake in Sarepta Therapeutics in the fourth quarter worth about $25,000. iSAM Funds UK Ltd bought a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at approximately $25,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $27,000. Finally, Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% during the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.